End­ing a gru­el­ing 10-year drought, Sanofi fi­nal­ly wins an OK for an in-house can­cer drug

Sanofi has snagged an FDA ap­proval for a top drug in its pipeline, end­ing a 10-year drought of home-grown can­cer drug ap­provals as the new team in charge looks to re­boot one of the in­dus­try’s per­pet­u­al lag­gards.

The agency stamped an ear­ly OK on isat­ux­imab, a CD38 drug that will now be­gin a mar­ket ri­val­ry with J&J’s mar­ket lead­ing Darza­lex un­der the name Sar­clisa. It’s ap­proved as a 3rd line treat­ment for mul­ti­ple myelo­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER